(MENAFN- Investor Brand Network) Shares of iSpecimen Inc. (NASDAQ:ISPC) traded today at $18.50, eclipsing its 52-week high. So far today approximately 13.3 million shares have been exchanged, as compared to an average 30-day volume of 3.1 million shares.
In the past 52 weeks, shares of iSpecimen Inc. have traded between a low of $4.75 and a high of $18.50 and is now at $11.67, which is 146% above that low price.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, tissues, and living cells for their research, with the available biospecimens. Its iSpecimen Marketplace platform solves this problem and transforms the biospecimen procurement process to accelerate medical discovery.
Based on a current price of $11.67, iSpecimen Inc. is currently 74.1% above its average consensus analyst price target of $3.02.
Receive IBN Spotlights –“Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights , please visit
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years . Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series . With a proven track record serving 500+ client partners , IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.